Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
Journal of the American Chemical Society · 02.08.2023 · 145 (30) · 16610-16620
DOI: 10.1021/jacs.3c03886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 18.07.2023. Verfasst von Mikimasa Tanada und 24 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Chugai Pharmaceutical Co. Ltd., 216, Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa 244-8602, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Peptides. Die Arbeit wurde bisher 189-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Cyclic peptides as a therapeutic modality are attracting a lot of attention due to their potential for oral absorption and accessibility to intracellular tough targets. Here, starting with a drug-like hit discovered using an mRNA display library, we describe a chemical optimization that led to the orally available clinical compound known as LUNA18, an 11-mer cyclic peptide inhibitor for the intracellular tough target RAS. The key findings are as follows: (i) two peptide side chains were identified that each increase RAS affinity over 10-fold; (ii) physico-chemical properties (PCP) including Clog P can be adjusted by side-chain modification to increase membrane permeability; (iii) restriction of cyclic peptide conformation works effectively to adjust PCP and improve bio-activity; (iv) cellular efficacy was observed in peptides with a permeability of around 0.4 × 10-6 cm/s or more in a Caco-2 permeability assay; and (v) while keeping the cyclic peptide's main-chain conformation, we found one example where the RAS protein structure was changed dramatically through induced-fit to our peptide side chain. This study demonstrates how the chemical optimization of bio-active peptides can be achieved without scaffold hopping, much like the processes for small molecule drug discovery that are guided by Lipinski's rule of five. Our approach provides a versatile new strategy for generating peptide drugs starting from drug-like hits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Division, Chugai Pharmaceutical Co. Ltd., 216, Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa 244-8602, Japan.
ORCID-Profile: Mikimasa Tanada, Toshiya Ito, Kenichi Nomura, Yoshikazu Nishimura
Zitieren
APA
Tanada, M., Tamiya, M., Matsuo, A., Chiyoda, A., Takano, K., Ito, T., Irie, M., Kotake, T., Takeyama, R., Kawada, H., Hayashi, R., Ishikawa, S., Nomura, K., Furuichi, N., Morita, Y., Kage, M., Hashimoto, S., Nii, K., Sase, H., …, & Shiraishi, T. (2023). Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. Journal of the American Chemical Society, 145(30), 16610-16620. https://doi.org/10.1021/jacs.3c03886
Vancouver
Tanada M, Tamiya M, Matsuo A, Chiyoda A, Takano K, Ito T, et al. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. Journal of the American Chemical Society. 2023;145(30):16610-16620. doi:10.1021/jacs.3c03886
BibTeX
@article{Tanada2023,
author = {Tanada, Mikimasa and Tamiya, Minoru and Matsuo, Atsushi and Chiyoda, Aya and Takano, Koji and Ito, Toshiya and Irie, Machiko and Kotake, Tomoya and Takeyama, Ryuuichi and Kawada, Hatsuo and Hayashi, Ryuji and Ishikawa, Shiho and Nomura, Kenichi and Furuichi, Noriyuki and Morita, Yuya and Kage, Mirai and Hashimoto, Satoshi and Nii, Keiji and Sase, Hitoshi and Ohara, Kazuhiro and Ohta, Atsushi and Kuramoto, Shino and Nishimura, Yoshikazu and Iikura, Hitoshi and Shiraishi, Takuya},
title = {Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor},
journal = {Journal of the American Chemical Society},
year = {2023},
volume = {145},
number = {30},
pages = {16610--16620},
doi = {10.1021/jacs.3c03886}
}
EUVIMED